UGN-301 (zalifrelimab)
Locally advanced or metastatic solid tumors
Phase 1/2Discontinued
Key Facts
Indication
Locally advanced or metastatic solid tumors
Phase
Phase 1/2
Status
Discontinued
Company
About UroGen Pharma
UroGen Pharma is a biopharmaceutical company pioneering novel treatments for uro-oncology, leveraging its proprietary RTGel™ technology platform to enable non-surgical, organ-sparing therapies. The company achieved a significant milestone with the FDA approval and commercialization of JELMYTO® for LG-UTUC, establishing a new standard of care. UroGen is advancing a pipeline of additional candidates, including UGN-102 for low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), and is publicly traded on the NASDAQ. Its mission is to transform patient care by providing alternatives to invasive surgeries.
View full company profileTherapeutic Areas
Other Locally advanced or metastatic solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| Systemic DNase I | Xenetic Biosciences | Pre-clinical |